Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (November 2022)
30 slides from Cognition Therapeutics's investor presentation, Nov 16, 2022
Slide 1: Developing disease-modifying medicines for degenerative disorders
Developing disease - modifying medicines for degenerative disorders November 2022
Slide 2: Forward-Looking Statements
2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 .. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or
Slide 3: Improved MoA against a Well Characterized Target
3 Improved MoA against a Well Characterized Target Protecting neurons from toxic stressors Neuronal synapse ‐ Amyloid oligomers ‐ α - synuclein oligomers ‐ Inflammatory mediators ‐ Oxidative stress Alzheimer's disease (AD) Dementia with Lewy bodies (DLB) Geographic atrophy (GA) Stressors Oligomer re
Slide 4: Compelling Investment Thesis
4 Protect synapses from toxic proteins and other stressors to facilitate restoration of neuronal function Compelling Investment Thesis Novel Approach Validated Science CT1812 Oral Once - Daily Oligomer receptor: well characterized target Highly brain penetrant Selective and saturable binding Strong
Slide 5: Rigorous Phase 2 Programs Underway and Planned
5 Clinical Study Indication Prevalence Funding SEQUEL (n=23) Mild - moderate AD ~ 5 million $5.4 Million SHINE (n=144) Mild - moderate AD ~ 5 million $30 Million START (n=540) MCI & Early AD ~ 5 million $81 Million SHIMMER (n=120) Mild - moderate DLB ~ 1.4 million $30 Million COG2201 (n=240) GA seco
Slide 6: Grants Fund Pipeline Advancement
6 Clinical Study Total Awarded Remaining Balance START (early AD) $ 81.0 Million $ 63.1 Million SHINE (mild/mod AD) $ 30.5 Million $ 8.8 Million SHIMMER (DLB) $ 29.5 Million $ 18.9 Million SEQUEL ( qEEG in AD) $ 5.4 Million $ 2.4 Million Other $ 3.8 Million $ 0.4 Million $ 150.2 Million $ 93.6 Milli
Slide 7: Multiple Near-term Catalysts
7 2022 2023 2024 2025 Multiple Near - term Catalysts SHINE Phase 2 (Mild - mod Alzheimer’s / n=144) SHINE/SPARC biomarker SEQUEL (Mild - mod AD / qEEG) SHIMMER Phase 2 (Mild - mod DLB / n=120) GA IND Data readout Data readout Data readout Data readout START (Early Alzheimer’s / n=540) GA/ dAMD (COG2
Slide 8: Our Approach: Alzheimer's Disease
Our Approach Alzheimer’s Disease
Slide 9: Aβ Cascade Drives Cognitive Loss in Alzheimer's
9 leads to oligomer receptor complex A β monomer A β Cascade Drives Cognitive Loss in Alzheimer’s Deficits in trafficking, autophagy, growth factor signaling Neuroinflammation Tau pathology A β plaques A β fibrils and protofibrils Ligand Receptor Synapse loss leading to cell death A β oligomer A β E
Slide 10: Multiple Approaches Address Toxic Interaction at the Receptor
10 CT1812 Small Molecule ACU193, ALZ801 Anti - oligomer Mab A β monomer Multiple Approaches Address Toxic Interaction at the Receptor Lecanemab Anti - protofibril Mab Donanemab Anti - plaque Mab Protect Synapses: • Small molecule ligand to the σ - 2 receptor displaces A β oligomers and prevents thei
Slide 11: CT1812 May Inhibit Oligomer-induced Toxicity
11 • Oral, QD small molecule • Penetrates the blood - brain barrier (BBB) • Binds selectively to the σ - 2 receptor • Displaces oligomers from neurons and prevents re - binding • Facilitates restoration of neuronal function CT1812 May Inhibit Oligomer - induced Toxicity • Izzo NJ, et al. Preclinical
Slide 12: CT1812: Alzheimer's Disease
Alzheimer’s Disease CT1812:
Slide 13: Rigorous Testing Supports Hypothesis
13 Rigorous Testing Supports Hypothesis Normal mouse + placebo Alzheimer’s mouse + placebo Alzheimer’s mouse + CT1812 Restores Cognitive Function in Mice A β oligomers Oligomers + CT1812 Placebo CT1812 Displaces Oligomers from Synapses in vitro CT1812 Vehicle Displaces Oligomers from AD Patient Brai
Slide 14: Clinical Results Support Targeting Oligomers
14 Clinical Results Support Targeting Oligomers CT1812 now tested in 220+ subjects. Majority have mild - to - moderate Alzheimer’s disease Target Engagement SNAP Study 1 : Log2 abundance Biologic Effect SPARC Study 2 : SHINE Study 3 : Clinical Signal SHINE Interim Data 3 : Placebo 100 mg 300 mg Conf
Slide 15: Clinical Evidence of Cognitive Benefit
15 Trend towards slower cognitive decline in CT1812 - treated vs placebo - treated participants as measured by ADAS - Cog 11 Clinical Evidence of Cognitive Benefit SHINE interim analysis (n=24) yields promising evidence Placebo CT1812 100 mg Day 0 6 months 1:1:1 Study Design (n=144) Screening: Labs,
Slide 16: SEQUEL (COG0202): Impact on Brain Wave Activity
16 • Design: two - group cross - over design in patients with mild - to - moderate AD • Single site: VUmc Alzheimer’s Center (PI: E. Vijverberg , MD, PhD) • Objective: evaluate changes in synaptic function through quantitative EEG, as reflected by relative theta power • Funding: $5.4M NIA grant awar
Slide 17: START: Impact on Cognitive Decline in Early AD
17 • Design: randomized, double - blind, placebo - controlled Phase 2 study in individuals with early - to - mild AD • Multi - site: 50 - 60 U.S. sites including ACTC centers of excellence • Objective: powered to show change in cognition: slowing or halting cognitive decline • Funding: $81M NIA gran
Slide 18: Dementia with Lewy Bodies - CT1812: Beyond Alzheimer's Disease
Dementia with Lewy Bodies CT1812: Beyond Alzheimer’s Disease
Slide 19: Synucleinopathies are 2nd only to AD in Prevalence
19 • In the U.S., approximately 13 million people have a form of dementia 1 - Dementia with Lewy bodies (DLB): 1.4 million - Parkinson’s disease: 1 million • Direct healthcare costs: - DLB: $31.5 billion 2 - PD: $25 billion 3 Synucleinopathies are 2nd only to AD in Prevalence Parkinson's Disease DLB
Slide 20: σ-Modulators May be Disease Modifying in Synucleinopathies
20 σ - 2 Modulators May be Disease Modifying in Synucleinopathies Cellular evidence that σ - 2 modulators have a beneficial impact - synuclein oligomers - synuclein oligomers + CT1812 - Synuclein oligomers in red Limegrover CS, et al. J Neurosci Res. 2021. doi : 10.1002/jnr.24782 α - synuclein oligo
Slide 21: SHIMMER: NIA Award of $30M Validates Study in DLB
21 • Design: randomized, double - blind, placebo - controlled, Phase 2 study in people with mild - to - moderate DLB • Multi - site: 30 center in the US, including LBDA centers of excellence (PI: J.E. Galvin, MD, MPH) • Objective: evaluate changes in cognition and function • Status: Over 50% of site
Slide 22: Dry Age-related Macular Degeneration - CT1812: Beyond Alzheimer's Disease
Dry Age - related Macular Degeneration CT1812: Beyond Alzheimer’s Disease
Slide 23: Translating Protective Potential of σ-2 to the Eye
23 Translating Protective Potential of σ - 2 to the Eye May block effects of toxic stressors on retinal pigment epithelial cells RPE cell ‐ Amyloid oligomers ‐ α - synuclein oligomers ‐ Inflammatory mediators ‐ Oxidative stress Alzheimer's disease Dementia with Lewy bodies Geographic atrophy Stresso
Slide 24: Rationale for σ-2 Modulators in Geographic Atrophy
24 σ - 2 receptors: • Expression: in RPE cells, retinal ganglion cells, photoreceptors in retina • Biology: Regulates autophagy, protein trafficking, lipid metabolism dysregulated in AMD • Target validation: TMEM97 knockdown is protective • Human genetics: Linked to dry AMD Rationale for σ - 2 Modul
Slide 25: Non-invasive Oral Small Molecule; Retinal and Brain Concentrations
25 • PK/PD: therapeutic levels of CT1812 achieved in retina with >80% receptor occupancy • Clinical biomarker support: analyses showed differential movement of proteins involved in dry AMD • Preclinical data: regulates cell survival and inflammatory pathways, rescues trafficking deficits Non - invas
Slide 26: σ-Receptor Modulators Rescue RPE Lysosomal Trafficking Deficits
26 σ - 2 Receptor Modulators Rescue RPE Lysosomal Trafficking Deficits Receptor - bound POS Lysosome (LAMP 1/2) Autophagy Body (LC3b) Early Compartment ( Rab 5) Rab 7 12 24 36 48 0.0 0.2 0.4 0.6 0.8 1.0 Time (hr) POS in LC3B+ autophagy bodies * * 12 24 36 48 0.0 0.2 0.4 0.6 0.8 1.0 Time (hr) POS in
Slide 27: Planned Phase 2 (COG2201) in dry AMD and Geographic Atrophy
27 Planned Phase 2 (COG2201) will Assess CT1812 in dry AMD and Measurable Geographic Atrophy Assessments such as: Change in GA lesion Low luminance visual acuity (LLVA) Best - corrected visual acuity (BCVA) Study Drug Administration Screening: Age: ≥ 50 Diagnosis of dry AMD BCVA ≥ 24 letters (ETDRS)
Slide 28: Financial Position
Financial Position Financials as of September 30, 2022 • Cash and Cash Equivalents: $46.6 million • Expected cash runway into the first half of 2024 Grant funding for CT1812 studies as of Sep 30, 2022 • Preclinical through Phase 2: appx $ 171.0 million − Approximate funding used: ($77.4 million) − R
Slide 29: Cognition Therapeutics in Summary
29 Cognition Therapeutics - in Summary Targeting unmet needs in age - related degenerative disorders of the central nervous system and retina such as Alzheimer’s disease, DLB, GA secondary to dry AMD, and Parkinson’s disease Functionally distinct therapeutic approach focused on the sigma - 2 (σ - 2)
Slide 30: Thank You
Thank You Andy Einhorn Interim CFO 973 - 879 - 8240 aeinhorn@cogrx.com Lisa Ricciardi President & CEO 917 - 658 - 5789 lricciardi@cogrx.com
Cognition Therapeutics — Investor Presentation (November 2022) on 6ix